A Study of Yttrium-90 Radioactive Resin Microspheres to Treat Colorectal Adenocarcinoma Metastatic to the Liver [clinicaltrials:NCT01098422]

Bio2RDF identifier

NCT01098422

http://www.w3.org/2001/XMLSchema#string

Bio2RDF namespace

clinicaltrials

http://www.w3.org/2001/XMLSchema#string

Bio2RDF uri

http://bio2rdf.org/clinicaltrials:NCT01098422

http://www.w3.org/2001/XMLSchema#string

identifiers.org URI

NCT01098422

actual enrollment [clinicaltrials_vocabulary:actual-enrollment]

10

http://www.w3.org/2001/XMLSchema#integer

arm group [clinicaltrials_vocabulary:arm-group]

NCT01098422 arm group 7ad1e5ce556dd73c2d4578d84c26db0b [clinicaltrials_resource:NCT01098422/arm-group/7ad1e5ce556dd73c2d4578d84c26db0b]

authority [clinicaltrials_vocabulary:authority]

clinicaltrials_resource:d942c8692d257084abf3ac87279faff6

brief summary [clinicaltrials_vocabulary:brief-summary]

The purpose of this stu ...... ent second line chemotherapy.

http://www.w3.org/2001/XMLSchema#string

brief title [clinicaltrials_vocabulary:brief-title]

A Study of Yttrium-90 Radioact ...... cinoma Metastatic to the Liver

http://www.w3.org/2001/XMLSchema#string

clinicaltrials_vocabulary:primary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:primary-outcome]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:0810661c7631a70590d518e4b3491aad]

clinicaltrials_vocabulary:secondary outcome [clinicaltrials_vocabulary:clinicaltrials_vocabulary:secondary-outcome]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:21b4daa06f4c9cd5a1a03ff3e77d20d1]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:300163f8715cf5c34e266dad512cbfab]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:33c0b6817cffd6ca50523f779c582e2a]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:3481b896ab315aec56584a7b53e33294]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:4c490704e6ec3726830d2e6e13524b59]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:4e255fe942a712a9c14ad800f133989f]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:6190aa01caa366ac473e7d9e31f72227]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:6fe267d5362bd6675fe8a9a50265fdc9]

Progression-free survival assessed by Response Evaluation Criteria in Solid Tumors (RECIST) criteria using Computerized Tomography (CT) assessment of tumor(s) at 6 months since the diagnosis date of disease progression on first-line therapy. 4 years [clinicaltrials_resource:b06c47b457d53c9af6881d19962b08b8]

collaborator [clinicaltrials_vocabulary:collaborator]

Tony Reid, M.D., Ph.D. [clinicaltrials_resource:217e7b91723e24da8ff7927b73243b20]

completion date [clinicaltrials_vocabulary:completion-date]

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

detailed description [clinicaltrials_vocabulary:detailed-description]

This is a phase II, sin ...... ks post the second treatment.

http://www.w3.org/2001/XMLSchema#string

download date [clinicaltrials_vocabulary:download-date]

ClinicalTrials.gov processed this data on August 10, 2015

http://www.w3.org/2001/XMLSchema#string

eligibility [clinicaltrials_vocabulary:eligibility]

eligibility for clinicaltrials:NCT01098422 [clinicaltrials_resource:c959d2405a1041c2ac54c09178507527]

firstreceived date [clinicaltrials_vocabulary:firstreceived-date]

2010-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

has expanded access [clinicaltrials_vocabulary:has-expanded-access]

No

http://www.w3.org/2001/XMLSchema#string

intervention [clinicaltrials_vocabulary:intervention]

Yttrium-90 Radioactive Resin Microspheres [clinicaltrials_resource:7be8b8b7921ac2400842b38c6b6f74b1]

is fda regulated [clinicaltrials_vocabulary:is-fda-regulated]

Yes

http://www.w3.org/2001/XMLSchema#string

is section 801 [clinicaltrials_vocabulary:is-section-801]

Yes

http://www.w3.org/2001/XMLSchema#string

keyword [clinicaltrials_vocabulary:keyword]

Yttrium-90

http://www.w3.org/2001/XMLSchema#string

carcinoma

http://www.w3.org/2001/XMLSchema#string

colorectal

http://www.w3.org/2001/XMLSchema#string

liver

http://www.w3.org/2001/XMLSchema#string

metastasis

http://www.w3.org/2001/XMLSchema#string

microspheres

http://www.w3.org/2001/XMLSchema#string

lastchanged date [clinicaltrials_vocabulary:lastchanged-date]

2015-06-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

lead sponsor [clinicaltrials_vocabulary:lead-sponsor]

Tony Reid, M.D., Ph.D. [clinicaltrials_resource:217e7b91723e24da8ff7927b73243b20]

location [clinicaltrials_vocabulary:location]

The Rebecca and John Moores UCSD Cancer Center [clinicaltrials_resource:966c8eb421099da78609e1d68f9176d9]

nct id [clinicaltrials_vocabulary:nct-id]

NCT01098422

http://www.w3.org/2001/XMLSchema#string

number of arms [clinicaltrials_vocabulary:number-of-arms]

1

http://www.w3.org/2001/XMLSchema#integer

official title [clinicaltrials_vocabulary:official-title]

A Phase II Study of Yttrium-90 ...... -Line Combination Chemotherapy

http://www.w3.org/2001/XMLSchema#string

org study id [clinicaltrials_vocabulary:org-study-id]

71,960

http://www.w3.org/2001/XMLSchema#integer

overall official [clinicaltrials_vocabulary:overall-official]

Tony Reid, MD, PhD [clinicaltrials_resource:f77124f37bf4cce182cd361a9346d747]

overall status [clinicaltrials_vocabulary:overall-status]

Terminated [clinicaltrials_resource:fba9c4daa2dd29d1077d32d965320ac1]

oversight [clinicaltrials_vocabulary:oversight]

United States: Food and Drug Administration [clinicaltrials_resource:be4cea82cb21bbda79c939a4d720315b]

phase [clinicaltrials_vocabulary:phase]

Phase 2 [clinicaltrials_resource:56e0338b27a2d68f77402c88327b3f8d]

primary completion date [clinicaltrials_vocabulary:primary-completion-date]

2015-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

responsible party [clinicaltrials_vocabulary:responsible-party]

[clinicaltrials_resource:6851783053406128ea9586bd59c2b618]

source [clinicaltrials_vocabulary:source]

University of California, San Diego [clinicaltrials_resource:bf7ffba481d94865ea4c0d70066c0e26]

start date [clinicaltrials_vocabulary:start-date]

2010-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

study design [clinicaltrials_vocabulary:study-design]

clinicaltrials:NCT01098422 study design [clinicaltrials_resource:22db2069593ef8d75583a67bfbfb220f]

study type [clinicaltrials_vocabulary:study-type]

Interventional [clinicaltrials_resource:843ac00ae5d0b7c7defb84fb42c2ce31]

url [clinicaltrials_vocabulary:url]

NCT01098422

verification date [clinicaltrials_vocabulary:verification-date]

2015-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

why stopped [clinicaltrials_vocabulary:why-stopped]

Halted due to slow enrollment

http://www.w3.org/2001/XMLSchema#string

identifier

clinicaltrials:NCT01098422

http://www.w3.org/2001/XMLSchema#string

title

A Study of Yttrium-90 Radioact ...... cinoma Metastatic to the Liver

@en

inDataset

clinicaltrials_resource:bio2rdf.dataset.clinicaltrials.R3

type

Clinical Study [clinicaltrials_vocabulary:Clinical-Study]

clinicaltrials resource [clinicaltrials_vocabulary:Resource]